Latest Ratios: P/E Ratio -2.8x · EV/EBITDA N/A · ROE N/A. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $87M | $308M | — | — | — | — |
| Enterprise Value | $153M | $754M | — | — | — | — |
| P/E Ratio → | -2.77 | — | — | — | — | — |
| P/S Ratio | 1.47 | 0.77 | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.88 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 13.1% | 13.1% | 13.9% | 12.7% | 22.4% | 24.4% |
| Operating Margin | -29.1% | -29.1% | -7.5% | -7.3% | -1.5% | -37.0% |
| Net Profit Margin | -53.2% | -53.2% | -41.9% | -47.7% | -51.2% | -87.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — |
| ROA | -276.5% | -276.5% | -254.8% | -253.0% | -369.5% | -975.6% |
| ROIC | — | — | — | — | — | — |
| ROCE | — | — | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -9.16 | -9.16 | -1.88 | -1.67 | -0.24 | -4.90 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.48 | 0.48 | 0.21 | 0.35 | 0.33 | 0.17 |
| Quick Ratio | 0.44 | 0.44 | 0.16 | 0.27 | 0.28 | 0.09 |
| Cash Ratio | 0.04 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 |
| Asset Turnover | — | 3.72 | 7.41 | 4.60 | 5.04 | 11.15 |
| Inventory Turnover | 41.98 | 41.98 | 32.17 | 20.96 | 23.23 | 20.06 |
| Days Sales Outstanding | — | 22.65 | 15.95 | 38.78 | 40.57 | 1.25 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $58M | $7M | $7M | $7M | $7M |
Imminent liquidity shortfall risk
Based on a P/S ratio of 0.20, the market appears to price POM as a distressed retail asset rather than a high-growth technology firm, suggesting that investors are heavily discounting the company's ability to achieve profitability given its current scale and deep net losses.
The low P/S multiple relative to broader healthcare peers indicates that the market is skeptical of the company's long-term margin expansion potential. This valuation suggests that the market views the current 12.37% revenue growth as insufficient to offset the high customer acquisition costs and structural margin pressures inherent in the business model.
As reported in financial statements, POM's 13.92% gross margin highlights a structural reliance on low-margin pharmaceutical distribution, which, when combined with a -41.85% net margin, suggests that the company's core operations are currently unable to cover its significant administrative and marketing overhead.
The wide gap between gross and net margins implies that the company is struggling to achieve the operating leverage necessary for sustainability. Investors should monitor whether the firm can pivot toward higher-margin medical services, as the current reliance on commodity drug sales appears to be a primary driver of its persistent bottom-line losses.
According to recent filings, POM holds only $7.65 million in cash against a $342 million revenue base, a liquidity profile that appears highly vulnerable and suggests the company may face an imminent need for external financing to maintain its current operational trajectory.
The limited cash buffer leaves the firm with little room to maneuver in the event of regulatory shifts or increased competitive pressure in the Chinese digital health market. This liquidity constraint warrants extreme caution, as the company's ability to fund its ongoing operations without dilutive capital raises remains highly questionable.
The most commonly misapplied metric for POM is the P/S ratio, which obscures the company's true nature as a low-margin pharmaceutical wholesaler rather than a high-margin software platform, leading to potential misinterpretations of its underlying business quality and long-term earnings potential.
Analysts should instead focus on the 'take rate' and unit economics of chronic patient retention, as these metrics better reflect the company's actual value creation. Relying on standard tech-sector valuation multiples risks ignoring the significant inventory and fulfillment costs that structurally constrain the firm's profitability compared to pure-play digital service providers.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying POM stock.
POMDOCTOR Ltd's current P/E ratio is -2.8x. This places it at the 50th percentile of its historical range.
Based on historical data, POMDOCTOR Ltd is trading at a P/E of -2.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
POMDOCTOR Ltd has 13.1% gross margin and -29.1% operating margin.